Is 2023 the Year for OTC Naloxone?
FDA Law Blog
FEBRUARY 16, 2023
sales of naloxone from a wholesale distributor to a harm reduction program) from certain requirements under the Drug Supply Chain Security Act. All 19 members of the joint Advisory Committee agreed that the benefit-risk profile of Narcan Nasal Spray (NNS) is “supportive of its use as a nonprescription opioid overdose reversal agent.”
Let's personalize your content